ライフサイエンスコーパス: lactate dehydrogenase

1 aphic analysis of allosterically inhibited L-lactate dehydrogenase.

2 zyme for the study of reaction landscapes is lactate dehydrogenase.

3 er than three organ sites and lower baseline lactate dehydrogenase.

4 autolysis of cells using a cytosolic enzyme lactate dehydrogenase.

5 lveolar lavage neutrophils, eosinophils, and lactate dehydrogenase.

6 e pool was observed, catalyzed by the enzyme lactate dehydrogenase.

7 orionic gonadotropin, alpha-fetoprotein, and lactate dehydrogenase.

8 ion of the prototypical bulk autophagy cargo lactate dehydrogenase.

9 relating with the increased transcription of lactate dehydrogenases.

10 pyruvate dehydrogenase, [(13)C]bicarbonate), lactate dehydrogenase ([1-(13)C]lactate), and alanine tr

11 Studies with isolated lactate dehydrogenase-1 and malate dehydrogenase-2 revea

12 rt 2.8-A- and 1.8-A-resolution structures of lactate dehydrogenase (145 kDa) and glutamate dehydrogen

13 Le Dudal and colleagues demonstrate that the lactate dehydrogenase 5 inhibitor (LDH5) stiripentol red

14 et syndrome, possibly by inhibiting neuronal lactate dehydrogenase 5 isoenzyme.

15 ents who received D + T with baseline normal lactate dehydrogenase (5 years, 45%) and normal lactate

16 ase (34.3 +/- 16.6 vs 24.5 +/- 16.8U/L), and lactate dehydrogenase (510.8 +/- 33 vs 292.4 +/- 29).

17 orionic gonadotropin (hCG) 151,111 IU/L, and lactate dehydrogenase 588 U/L.

18 of the genes encoding hexokinase 1 (HK1) and lactate dehydrogenase A (LDHA) - both of which regulate

19 ssive tumors to enhanced glycolytic flux and lactate dehydrogenase A (LDHA) activity (Warburg effect)

20 Lactate dehydrogenase A (LDHA) has been reported to be i

21 pproaches, we show that lactate reduction by lactate dehydrogenase A (LDHA) inactivation heightens ty

22 Here, we show that lactate dehydrogenase A (LDHA) is induced in activated T

23 olytic as manifested by strong expression of lactate dehydrogenase A (LDHA) that converts pyruvate to

24 t that phosphorylation-induced activation of lactate dehydrogenase A (LDHA), an enzyme that catalyses

25 monophosphate synthetase (UMPS), as well as lactate dehydrogenase A (LDHA), establishing a mechanism

26 n cells also generate G3P upon inhibition of lactate dehydrogenase A (LDHA), our findings hint at a c

27 housekeeping genes - such as those encoding lactate dehydrogenase A (LDHA), solute transporter MCT1,

28 Expression of lactate dehydrogenase A (LDHA), which catalyzes (13)C la

29 bolic pathways with marked overexpression of lactate dehydrogenase A (LDHA).

30 ng of cell metabolism towards glycolysis and lactate dehydrogenase A (LDHA).

31 Small interfering RNA ablation of lactate dehydrogenase A attenuated HDM-induced increases

32 ycolytic enzymes, with notable expression of lactate dehydrogenase A occurring in the airway epitheli

33 es key beta cell "disallowed" genes, such as lactate dehydrogenase A We propose that C2CD4A is a tran

34 is enzymes pyruvate dehydrogenase kinase and lactate dehydrogenase A within cortical and hippocampal

35 c downregulation decreased the expression of lactate dehydrogenase A, the enzyme catalyzing the conve

36 a targets VEGF-A, glucose transporter-1, and lactate dehydrogenase A.

37 ed the contributions of macrophage-expressed lactate dehydrogenase-A (LDH-A) to tumor formation in a

38 ntially metabolized to lactate by the enzyme lactate dehydrogenase-A (LDH-A), suggesting a possible v

39 /fructose-2,6-bisphosphatase-3 (PFKFB3), and lactate dehydrogenase-A expression.

40 PL flux correlated significantly with higher lactate dehydrogenase activity and mRNA expression of Ld

41 associated with changes in levels of NADH or lactate dehydrogenase activity in tumors.

42 okinase activity by 33% in all mice, whereas lactate dehydrogenase activity increased by 71% in hypox

43 The ratio between the free and the total lactate dehydrogenase activity is a promising predictive

44 In contrast to pO(2) and (18)F-FDG uptake, lactate dehydrogenase activity was distributed relativel

45 t although fetal plasma fructose and hepatic lactate dehydrogenase activity were greater in cortisol-

46 eral blood smear, increased plasma levels of lactate dehydrogenase activity, blood urea nitrogen, and

47 tissue compared to the cell-line, a loss of lactate dehydrogenase activity, but not of alpha-d-gluco

48 , indicated by a rise in pyruvate kinase and lactate dehydrogenase activity, indicating a compensator

49 une checkpoint pathways and greater rates of lactate dehydrogenase activity.

50 ion injury, involving attenuated variable of lactate dehydrogenase, alanine, aspartate, and cytokine

51 evaluated with three other dehydrogenases (d-lactate dehydrogenase, alcohol dehydrogenase, and format

52 ars was 62% in patients with normal baseline lactate dehydrogenase and 63% in patients with a complet

53 p until the end of treatment (a total of 137 lactate dehydrogenase and 77 neuron-specific enolase obs

54 Cellular injury markers lactate dehydrogenase and aspartate aminotransferase wer

55 , lower hemoglobin and platelets, and higher lactate dehydrogenase and beta-2-microglobulin.

56 asured by optical imaging and by analysis of lactate dehydrogenase and caspase-cleaved cytokeratin 18

57 enhanced native refolding of urea-denatured lactate dehydrogenase and heat-denatured glucose-6-phosp

58 This process was accomplished by deletion of lactate dehydrogenase and heterologous expression of a C

59 The effect of freeze-thawing on cytosolic lactate dehydrogenase and lysosomal alpha-d-glucosidase

60 rogenase, whereas l-(S)-2-HG is generated by lactate dehydrogenase and malate dehydrogenase in respon

61 ncluding enolase, pyruvate kinase M2 (PKM2), lactate dehydrogenase and monocarboxylate transporter.

62 d extractions, multienzyme systems linked to lactate dehydrogenase and NAD(+) generation, and HPLC-ba

63 lene green) and a hydrogel matrix containing lactate dehydrogenase and nicotinamide adenine dinucleot

64 her protein carbonyls, 3-nitrotyrosine, PAR, lactate dehydrogenase and proteins in bronchoalveolar la

65 PEB1 aspartate/glutamate transporter, LutABC lactate dehydrogenase and PutA proline dehydrogenase bec

66 membrane-bound respiratory enzymes, LdhD (D-lactate dehydrogenase) and LldD (L-lactate dehydrogenase

67 ed that cytoplasmic LdhA (NAD(+)-dependent D-lactate dehydrogenase) and the membrane-bound respirator

68 (14;20), four (4%) of 100 had elevated serum lactate dehydrogenase, and 17 (17%) had two or more feat

69 nce status >1, extranodal sites >1, elevated lactate dehydrogenase, and B symptoms at diagnosis were

70 serum creatinine, alanine aminotransferase, lactate dehydrogenase, and creatine kinase.

71 We identified markers of inflammation, lactate dehydrogenase, and creatinine as the variables m

72 transferase (AST), alanine aminotransferase, lactate dehydrogenase, and creatinine correlated to fata

73 ating levels of alanine aminotransferase and lactate dehydrogenase, and inflammatory mediators such a

74 e pathways, such as glycolysis, flux through lactate dehydrogenase, and the citric acid cycle (as inf

75 , LdhD (D-lactate dehydrogenase) and LldD (L-lactate dehydrogenase) are correctly annotated.

76 ormalities, such as lymphopenia and elevated lactate dehydrogenase, are common, but nonspecific.

77 , aldolase A and pyruvate kinase, as well as lactate dehydrogenase, are enriched at the C. trachomati

78 Whereas initial high blood counts and high lactate dehydrogenase as an indicator for high prolifera

79 ADH Sink" was created using Escherichia coli lactate dehydrogenase as an NADH scavenger, thereby prev

80 Aspartate aminotransferase and lactate dehydrogenase as injury markers were below the d

81 evidenced by increased creatinine kinase and lactate dehydrogenase, as well as expression of monocyte

82 Neo1 mice showed attenuated serum levels of lactate dehydrogenase, aspartate, alanine, and proinflam

83 rfusion injury, as measured by the levels of lactate dehydrogenase, aspartate, and alanine aminotrans

84 s evaluated using histology, serum levels of lactate dehydrogenase, aspartate, and alanine aminotrans

85 Lactate dehydrogenase assay (LDH), electronic microscopy

86 The results of a lactate dehydrogenase assay indicated that exposure to t

87 on receptors and intracellular signals, with lactate dehydrogenase assay performed for cell damage, a

88 ucing sugars and phenolic compounds, and the lactate dehydrogenase assay was invalidated by honey oxi

89 almonella mutation assays) and cytotoxicity (lactate dehydrogenase assay) to assess the toxicity of t

90 Cell toxicity was measured using a lactate dehydrogenase assay.

91 l)-2,5-diphenyltetrazolium bromide) and LDH (lactate dehydrogenase) assays performed with the device

92 ts had stage IV disease and 42% had elevated lactate dehydrogenase at BRAFi/MEKi initiation.

93 Crystal structures of Babesia microti lactate dehydrogenase BmLDH reveal a critical role for A

94 o demonstrate that the reaction landscape of lactate dehydrogenase branches at multiple points creati

95 generated by the reduction of pyruvate via l-lactate dehydrogenase, but this enzyme does not efficien

96 ance of high glycolytic rates depends on the lactate dehydrogenase-catalyzed regeneration of NAD(+) f

97 Other factors, such as lactate dehydrogenase, circulating myeloblasts, platelet

98 Diagnosis with PfHRP2/Pf-Plasmodium lactate dehydrogenase combination RDTs did not select fo

99 d be moderated by using PfHRP2/Pf-Plasmodium lactate dehydrogenase combination RDTs.

100 tive CR showed that lower prelymphodepletion lactate dehydrogenase concentration (hazard ratio [HR],

101 Randomisation was stratified by lactate dehydrogenase concentration and geographical reg

102 The patient's lactate dehydrogenase concentration was 327 U/L (normal

103 n was stratified by ECOG performance status, lactate dehydrogenase concentration, and BRAF(V600) muta

104 age, tumor stage, performance status, serum lactate dehydrogenase concentration, and number of extra

105 urvival when adjusted for sex, age, baseline lactate dehydrogenase concentration, comorbidity, mono-o

106 Furthermore, lactate dehydrogenase cytotoxicity assay, live-dead cell

107 d-Lactate dehydrogenase (d-LDH) is encoded by a single gen

108 ermine the biomarkers C-reactive protein and lactate dehydrogenase (detection limits of 0.1, 87, and

109 he mitochondrial respiratory chain via the D-lactate dehydrogenase Dld1.

110 ting expression of the Drosophila homolog of lactate dehydrogenase (dLdh).

111 Recombinant COR15 proteins stabilize lactate dehydrogenase during freezing in vitro.

112 ed International Prognostic Index, including lactate dehydrogenase, Eastern Cooperative Oncology Grou

113 Dld2 and Dld3, both currently annotated as D-lactate dehydrogenases, efficiently oxidized D-2HG to al

114 ucation, hemoglobin A1C, C-reactive protein, lactate dehydrogenase, electrolytes, or urine albumin.

115 In this article, we show that infection with lactate dehydrogenase-elevating virus, a benign mouse ar

116 However, the lactate dehydrogenase-elevating virus-induced exacerbati

117 were formed, providing a stable support for lactate dehydrogenase entrapment while lowering the rate

118 n and functionalized with glutaraldehyde and lactate dehydrogenase enzyme was immobilized on the alde

119 jump results yields an unprecedented view of lactate dehydrogenase enzymology, confirming the timesca

120 We show here that d-lactate dehydrogenase from Staphylococcus epidermidis re

121 ; release of IL-1beta, IL-18, caspase-1, and lactate dehydrogenase from the cell; and real-time analy

122 With syngas, the upregulated (R)-lactate dehydrogenase gene represents a route of electro

123 aminotransferase, alanine aminotransferase, lactate dehydrogenase, glucose, lactate, and pH) with gr

124 Catfish L-lactate dehydrogenase, glyceraldehyde-3-phosphate dehydr

125 eatment, beta-2 microglobulin >= 5 mg/L, and lactate dehydrogenase > 250 U/L.

126 each; serum beta(2)-microglobulin >=5 mg/dL, lactate dehydrogenase >upper limit of normal, haemoglobi

127 Multivariate analysis showed high lactate dehydrogenase, >/=3 prior treatment lines, and l

128 regular need for pain medication, and higher lactate dehydrogenase had a negative impact on the thera

129 tein, beta-human chorionic gonadotropin, and lactate dehydrogenase had sensitivities of less than 50%

130 Group performance status of 2-4 and elevated lactate dehydrogenase had shorter progression-free and o

131 Ninety minutes lactate dehydrogenase had the strongest correlation with

132 Human lactate dehydrogenase (hLDH5), a glycolytic enzyme respo

133 tio [HR], 2.3; 95% CI, 1.6 to 3.4), elevated lactate dehydrogenase (HR, 2.3; 95% CI, 1.4 to 3.8), B s

134 of a dual-band (histidine-rich protein-2/pan-lactate dehydrogenase [HRP2/pLDH]) rapid diagnostic test

135 ; lymphopenia in 45%; and elevated levels of lactate dehydrogenase in 82%, aspartate aminotransferase

136 erexpression of a Lactobacillus helveticus L-lactate dehydrogenase in M. buryatense resulted in an in

137 Increased release of lactate dehydrogenase in OmpU-treated cells indicates th

138 biosensor was developed for the detection of lactate dehydrogenase in serum using a nonporous, oxygen

139 Stx2 induced the release of hemoglobin and lactate dehydrogenase in whole blood, indicating hemolys

140 ventional fluid biomarkers (pH, glucose, and lactate dehydrogenase) in parapneumonic effusions.Method

141 Administration of a lactate dehydrogenase inhibitor blunted lactate producti

142 or IV disease, >1 extranodal site, elevated lactate dehydrogenase, International Prognostic Index (I

143 This effect was followed by a decrease in lactate dehydrogenase isoform M (LDH-M) activity and an

144 Therefore, interpreting T-jump results of lactate dehydrogenase kinetics has required extensive co

145 ncrease in bronchoalveolar protein (48%) and lactate dehydrogenase (LDH) (68%) following 72 hours of

146 aspartate transaminase (P = .0040); elevated lactate dehydrogenase (LDH) (P < .0001); and increased p

147 Lactate dehydrogenase (LDH) accounts for the fermentativ

148 cellular lactate in all cases, and unchanged lactate dehydrogenase (LDH) activity and increased NAD+/

149 Cell viability, cell number, lactate dehydrogenase (LDH) activity, cell necrosis, tra

150 lung damage, as measured by protein leak and lactate dehydrogenase (LDH) activity.

151 ds by increasing carbohydrate metabolism and lactate dehydrogenase (LDH) activity.

152 ctivity of aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and creatine kinase (CK), wh

153 Increased levels of lactate dehydrogenase (LDH) and decreased levels of succ

154 sm and aerobic glycolysis, robustly inducing lactate dehydrogenase (LDH) and lactate production, wher

155 Next, genes encoding lactate dehydrogenase (ldh) and pyruvate oxidase (poxB)

156 as of sufficient magnitude to increase serum lactate dehydrogenase (LDH) and was oxidative in nature

157 stidine-rich protein 2 (HRP2), aldolase, and lactate dehydrogenase (LDH) antigens were analyzed by Ba

158 oxia inducible factor 1alpha (HIF1alpha) and Lactate dehydrogenase (LDH) are required for macrophage

159 We identified lactate dehydrogenase (LDH) as a new functional target o

160 ime points using fluorescence microscopy and Lactate dehydrogenase (LDH) assay on the supernatant.

161 Cellular viability, autophagy, lactate dehydrogenase (LDH) assay, and mammalian target

162 exan parasites, B. microti lacks a canonical lactate dehydrogenase (LDH) but instead expresses a uniq

163 FOXM1 drives expression of lactate dehydrogenase (LDH) but not hexokinase 2 (HK-II)

164 Lactate dehydrogenase (LDH) catalyzes the conversion of

165 Patients with normal lactate dehydrogenase (LDH) concentration and fewer than

166 We measured lactate dehydrogenase (LDH) concentration as a marker of

167 The release of lactate dehydrogenase (LDH) during brain death was reduc

168 g simulations have proposed that human heart lactate dehydrogenase (LDH) employs protein promoting vi

169 n 2 (HRP2) and the malaria-conserved antigen lactate dehydrogenase (LDH) for P. vivax and other malar

170 d to three independent prognostic variables: lactate dehydrogenase (LDH) higher than than normal, Int

171 titanium oxynitride (TiON) were modified for lactate dehydrogenase (LDH) immobilization using (3-amin

172 lize aerobic glycolysis, and the activity of lactate dehydrogenase (Ldh) is essential for HFSC activa

173 We demonstrate that lactate dehydrogenase (LDH) isoform 5 secreted by gliobl

174 In addition, FBSH-III inhibited lactate dehydrogenase (LDH) leakage and intracellular re

175 lar health and integrity: cell viability and lactate dehydrogenase (LDH) leakage.

176 howed that a lower pre-lymphodepletion serum lactate dehydrogenase (LDH) level and a favorable cytoki

177 A biomarker panel using CTC count and lactate dehydrogenase (LDH) level was shown to satisfy t

178 ndings of elevated D-dimer level or elevated lactate dehydrogenase (LDH) level were suspected of embo

179 High IL-6 level, C-reactive protein level, lactate dehydrogenase (LDH) level, ferritin level, d-dim

180 e occurrence of pump thrombosis and elevated lactate dehydrogenase (LDH) levels, LDH levels presaging

181 tosolic equilibrium with the products of the lactate dehydrogenase (LDH) reaction and the intermediat

182 ,5-diphenyl tetrazolium bromide (MTT) assay, lactate dehydrogenase (LDH) release assay, Hoechst 33342

183 iphenyltetrazolium bromide (MTT) assay and a lactate dehydrogenase (LDH) release assay, respectively.

184 re, the effect of 7l,q,r, and 8i in lowering lactate dehydrogenase (LDH) release induced by ischemia-

185 rmeability transition pore (MPTP) formation, lactate dehydrogenase (LDH) release, and necrotic cell d

186 e stress, and apoptosis were evaluated using lactate dehydrogenase (LDH) release, the fluorescent pro

187 to the cytosol, activation of caspase-3, and lactate dehydrogenase (LDH) release.

188 ter CD138 plasma cell purification and serum lactate dehydrogenase (LDH) to evaluate their prognostic

189 LEA3 was able to prevent the inactivation of lactate dehydrogenase (LDH) under heat, dehydration-rehy

190 ehyde-3-phosphate dehydrogenase (GAPDH) to L-lactate Dehydrogenase (LDH) using enzymes from different

191 on reduced graphene oxide (RGO-AuNPs) and l-lactate dehydrogenase (LDH) was developed for the sensin

192 Serum containing lactate dehydrogenase (LDH) was directly spotted on to t

193 s greater than 55 mg/dL (LR range, 7.1-250), lactate dehydrogenase (LDH) was greater than 200 U/L (LR

194 accumulate TMAO to protect proteins, such as lactate dehydrogenase (LDH), against hydrostatic pressur

195 The up-regulation of L-lactate dehydrogenase (LDH), an intracellular enzyme pre

196 aluated for prostate-specific antigen (PSA), lactate dehydrogenase (LDH), and CgA at baseline and in

197 ase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and thiobarbituric acid rea

198 Low serum albumin, elevated lactate dehydrogenase (LDH), high Creactive protein (CRP

199 Moreover, while release of lactate dehydrogenase (LDH), HMGB1, and IL-1beta occurre

200 elongation factor thermo-unstable (EF-Tu), l-lactate dehydrogenase (LDH), protein D (PD), and peptido

201 Five predictors (age, lactate dehydrogenase (LDH), sites of involvement, Ann A

202 ach involves targeting the glycolytic enzyme lactate dehydrogenase (LDH), which is overexpressed and

203 t" assays for glucose, total bile acids, and lactate dehydrogenase (LDH).

204 ttributed to the terminal glycolytic enzyme, lactate dehydrogenase (LDH).

205 series of pyrazole-based inhibitors of human lactate dehydrogenase (LDH).

206 entional melanoma serum biomarkers (S100 and lactate dehydrogenase [LDH]) perform poorly in patients

207 The parasite genome encodes two isoforms of lactate dehydrogenase (LDH1 and LDH2) and enolase (ENO1

208 n of the Hypoxia Inducible Factor HIF1alpha, lactate dehydrogenase LDH5, glucose transporter GLUT2, p

209 found that the loss of hexokinase (HK2) and lactate dehydrogenase (LDHA) expression, together with a

210 Lactate dehydrogenases (LDHs) are tetrameric enzymes of

211 d to the cytosol and converted to oxalate by lactate dehydrogenase, leading to kidney failure.

212 (less than 50 ng/mL v 50 ng/mL or more) and lactate dehydrogenase (less than 200 v 200 U/L or more).

213 R, 1.79; 95% CI ,1.35-2.38), and an elevated lactate dehydrogenase level (HR, 1.87; 95% CI, 1.27-2.77

214 14.4]; P = .035), d-dimer level (P < .001), lactate dehydrogenase level (P < .001), and C-reactive p

215 pecific antigen level (r = 0.556, P < .001), lactate dehydrogenase level (r = 0.534, P < .001), alkal

216 and multivariable analysis, increased serum lactate dehydrogenase level and histology for a metastat

217 Multivariate analysis identified serum lactate dehydrogenase level and the NOTCH1/FBXW7/RAS/PTE

218 LLH was defined by a discharge lactate dehydrogenase level of 400 to 700 U/L.

219 dgkin's lymphoma (stage III with an elevated lactate dehydrogenase level or stage IV) or acute leukem

220 evel was observed in 139 (88%), and elevated lactate dehydrogenase level was observed in 128 (81%).

221 LL, the four-gene oncogenetic classifier and lactate dehydrogenase level were independent prognostic

222 , number of organ sites with metastasis, and lactate dehydrogenase level) were significantly associat

223 Altered performance status, anemia, high lactate dehydrogenase level, "B" symptoms, histologic gr

224 ed with adverse prognostic factors (ie, high lactate dehydrogenase level, 17p deletion, and high-risk

225 se level, 1435 U/L (normal level, <140 U/L); lactate dehydrogenase level, 253 U/L (normal level, <240

226 stituting the MIPI, age, performance status, lactate dehydrogenase level, and WBC count, were confirm

227 neutrophil count, C-reactive protein level, lactate dehydrogenase level, distribution of lung diseas

228 ted adverse events, headache and an elevated lactate dehydrogenase level, occurred in 32% of the pati

229 tumor stage, tumor location (leg vs nonleg), lactate dehydrogenase level, type of therapy (with or wi

230 hypoalbuminemia, thrombocytopenia, and high lactate dehydrogenase level, yielded a better C statisti

231 iate analysis including M substage and serum lactate dehydrogenase level.

232 cell count, neutrophil/lymphocyte ratio, and lactate dehydrogenase level.

233 d brain metastases (20% v 14%) and increased lactate dehydrogenase levels (52% v 38%) at baseline; 41

234 HR 2.09; 95% CI 1.20-3.65; P = .010), higher lactate dehydrogenase levels (HR per mg/dL 1.002; 95% CI

235 and was significantly associated with lower lactate dehydrogenase levels (P = .002).

236 ry bypass (R = 0.12 and 0.15, respectively), lactate dehydrogenase levels at end cardiopulmonary bypa

237 icantly lower aspartate aminotransferase and lactate dehydrogenase levels compared with kidneys prese

238 interaction in PFS: Male patients with high lactate dehydrogenase levels derived significant benefit

239 ts with ES-SCLC, stratified by sex and serum lactate dehydrogenase levels, were randomly assigned to

240 ed bilirubin levels or clinical icterus, and lactate dehydrogenase levels.

241 nscriptional regulation of the respiratory l-lactate dehydrogenase LldD in vitro and in mouse models

242 B), that is distinct from the flavoprotein L-lactate dehydrogenase (LldD).

243 (FL) (n = 109; 8.2%) had fewer elevations in lactate dehydrogenase, lower International Prognostic In

244 tate aminotransferase were persistently low (lactate dehydrogenase < 100 U/L, below analyzer range; a

245 lternative, iron-sulfur cluster-containing L-lactate dehydrogenase (LutACB), that is distinct from th

246 In conclusion, lactate dehydrogenase may be used as a marker to both as

247 etrazolium-bromide cell viability assay, the lactate dehydrogenase membrane leakage assay and nitric

248 corporating simple clinical parameters (age, lactate dehydrogenase, number/sites of involvement, stag

249 Among these peptides, two were derived from lactate dehydrogenase, one from creatine kinase, and fou

250 logy Group performance status, disease site, lactate dehydrogenase, opioid analgesic use, albumin, he

251 nd point, including survival in the elevated lactate dehydrogenase or EGFR and ALK wild-type populati

252 ma exchange/infusion use, platelet count, or lactate dehydrogenase or haptoglobin levels.

253 teristic radiographic findings with elevated lactate dehydrogenase, or hospitalization for pneumonia

254 (nonbulky stage II, age >60 years, elevated lactate dehydrogenase, or World Health Organization perf

255 sk factor for POD24 at baseline was elevated lactate dehydrogenase (P < .001).

256 rich protein II (PfHRP-II) and P. falciparum lactate dehydrogenase (PfLDH) antigens are widely deploy

257 antitative detection of Plasmodiumfalciparum lactate dehydrogenase (PfLDH) in whole blood samples.

258 le-antigen (histidine-rich protein 2 and pan-lactate dehydrogenase pLDH [HRP2/pLDH]) RDT and microsco

259 atalyzed by the biomarker enzymes Plasmodium lactate dehydrogenase ( PLDH) and Plasmodium falciparum

260 -Plasmodium aldolase (pAldo), pan-Plasmodium lactate dehydrogenase (pLDH), and P. falciparum histidin

261 smodium aldolase (pAldo), and pan-Plasmodium lactate dehydrogenase (pLDH).

262 idine-rich protein-II (HRPII) and Plasmodium lactate dehydrogenase (pLDH).

263 filtration rate levels, and had higher serum lactate dehydrogenase, procalcitonin, and interleukin-6

264 ger tumors, decreased body weight, increased lactate dehydrogenase production, and severe leukopenia.

265 city), lung weight gain, levels of proteins, lactate dehydrogenase, protein carbonyl (marker of ROS),

266 Elevated lactate dehydrogenase, proteinuria on routine urinalysis

267 uccinate dehydrogenase activities, decreased lactate dehydrogenase, pyruvate kinase, creatine kinase,

268 helial cells, pH, D/L-lactate production and lactate dehydrogenase relative abundance were assessed.

269 tobacilli adhesion to epithelial cells and D-lactate dehydrogenase relative abundance.

270 MDA had no neurotoxic effects, determined by lactate dehydrogenase release and nitric oxide synthase

271 tissues is demonstrated by the low levels of lactate dehydrogenase release and retained histology, ac

272 cellular cytotoxicity (RMCC) was assessed by lactate dehydrogenase release assay of CD20+ Daudi cells

273 is-infected cells analyzed on the basis of a lactate dehydrogenase release assay, propidium iodide st

274 Results from lactate dehydrogenase release assays showed a dose- and

275 city, as measured both by (51)Cr release and lactate dehydrogenase release assays.

276 No significant lactate dehydrogenase release was found after P. gingiva

277 A significant increase of lactate dehydrogenase release was observed, especially a

278 interleukin-1beta [IL-1beta] secretion, and lactate dehydrogenase release) compared to that with the

279 de-induced liver injury (TNF-alpha, ALT, and lactate dehydrogenase release).

280 exposure increased the number of dead cells, lactate dehydrogenase release, and interleukin-8 (IL-8)

281 xic effects of EMD treatment were sampled by lactate dehydrogenase release.

282 ecreased Trypan blue exclusion and increased Lactate dehydrogenase release.

283 ected pre- and poststorage for assessment of lactate dehydrogenase release.

284 hondrial cytochrome c content with increased lactate dehydrogenase release.

285 ic rate and abundant mitochondria and that d-lactate dehydrogenase resides in the mitochondria of cel

286 bstrates for yeast alcohol dehydrogenase and lactate dehydrogenase, respectively, with reaction rates

287 the putative catalytic site of the encoded d-lactate dehydrogenase, resulting in augmented blood leve

288 The readthrough-extended lactate dehydrogenase subunit LDHBx can also co-import L

289 , creatinine kinase, C-reactive protein, and lactate dehydrogenase to those seen in H5N1 patients, wh

290 ngiopoietin-2 was associated with hemolysis (lactate dehydrogenase, total bilirubin) and inflammation

291 ary plasma cell leukaemia and elevated serum lactate dehydrogenase (two times the upper limit of norm

292 We aimed to assess if the simple formula-lactate dehydrogenase (U/L) x creatinine (mg/dL)/thrombo

293 n flux from pyruvate to lactate catalyzed by lactate dehydrogenase using hyperpolarized (13)C magneti

294 ion of an NADH-dependent dehydrogenase (i.e. lactate dehydrogenase), via EDC/S-NHS chemistry, for the

295 High pretreatment lactate dehydrogenase was frequently encountered in lymp

296 The outflow of a cytosolic enzyme, lactate dehydrogenase, was studied in sea bream fillets

297 rs, large-cell transformation, and increased lactate dehydrogenase) were independent prognostic marke

298 ntional pleural biomarkers (pH, glucose, and lactate dehydrogenase) when predicting the referral for

299 2, phosphofructokinase, pyruvate kinase, and lactate dehydrogenase), while at the same time suppressi

300 tate dehydrogenase (5 years, 45%) and normal lactate dehydrogenase with fewer than three organ sites